Overview

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Aciex Therapeutics, Inc.
Treatments:
Cetirizine
Criteria
Inclusion Criteria:

- positive bilateral conjunctival allergen challenge (CAC)reaction

Exclusion Criteria:

- known contraindications or sensitivities to the study medication or its components

- any ocular condition that, in the opinion of the investigator, could affect the
subjects safety trial parameters

- use of disallowed medication during the period indicated prior to the enrollment or
during the study